OR WAIT null SECS
Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.
Porton Advanced, a contract development and manufacturing organization (CDMO), has reached an agreement with Yinjia Biosciences, who is not only a raw material provider, but a company that offers diagnostics products for adjuvant therapies.
The deal aims to support development of core protein raw materials for cell and gene therapies (CGTs) and testing reagent products for quality control and evaluation systems to accelerate development and commercialization.
“We are glad to establish a strategic partnership with Yinjia Biosciences,” says Wang Yangzhou, PhD, CEO of Porton Advanced. “This strategic partnership will strengthen Porton Advanced’s CGT CDMO, and accelerate the development of innovative CGT therapeutics to deliver life-changing benefits to patients.”